The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Orchard Therapeutics Announces Reimbursement Agreement With Italian Medicines Agency For Libmeldy
Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced it has reached another historic reimbursement agreement with the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco
SMBC Nikko Downgrades Orchard Therapeutics to Neutral
SMBC Nikko downgrades Orchard Therapeutics (NASDAQ:ORTX) from Outperform to Neutral.
Orchard Therapeutics Plans To Seek Strategic Options For Immunodeficiency Programs, Cuts Workforce
Orchard Therapeutics plc (NASDAQ: ORTX) announced its
Recap: Orchard Therapeutics Q4 Earnings
Orchard Therapeutics (NASDAQ:ORTX) reported its Q4 earnings results on Wednesday, March 30, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
